知识产权纠纷引发5亿元索赔，一品红再遇考验

Core Viewpoint - Yipinhong Pharmaceutical Group Co., Ltd. is facing multiple challenges, including a lawsuit for intellectual property disputes amounting to 528.6 million yuan and a significant financial loss due to previous regulatory violations in drug procurement [1][4]. Group 1: Lawsuit Details - The lawsuit traces back to a cooperation agreement signed in October 2014 between Yipinhong Pharmaceutical and Huiyou International, establishing a joint venture for the development of a specific drug [2]. - Huiyou International claims that the intellectual property transferred to the joint venture was originally valued at 88 million yuan, leading to a compensation demand of 528 million yuan, which is six times the original valuation [3]. - Yipinhong asserts that it has fulfilled its payment obligations and has engaged a legal team to contest the lawsuit, believing that Huiyou International lacks the right to initiate the claim [3]. Group 2: Financial Performance - Yipinhong reported a net loss of 540 million yuan for the fiscal year 2024, marking its first loss since going public, with a net profit of -289 million yuan after excluding non-recurring items [4]. - The company attributes its financial downturn to various factors, including industry policy changes, market environment shifts, and increased R&D investments totaling approximately 325 million yuan, a 7.77% increase year-on-year [4]. - The company also faced a significant financial impact from healthcare refunds, amounting to 266 million yuan, which exceeded its net profit for 2023 [5]. Group 3: Regulatory Issues - In July 2024, Yipinhong's subsidiary was found to have violated regulations during a national drug procurement process, resulting in the suspension of its procurement qualifications for six months [5]. - The company has been placed on a "violation list" alongside other firms, further complicating its operational landscape [5]. - Despite the ongoing lawsuit, Yipinhong claims that it does not expect the legal proceedings to affect its daily operations and R&D activities [5].